PharmiWeb.com - Global Pharma News & Resources
01-May-2023

OmniAb to Report First Quarter 2023 Financial Results on May 11

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May 11, 2023 and will hold a conference call that same day beginning at 8:30 a.m. Eastern time.

Conference Call and Webcast Information

What:

 

OmniAb conference call to discuss financial results and business updates

 

 

 

Date:

 

Thursday, May 11, 2023

 

 

 

Time:

 

8:30 a.m. Eastern time

 

 

 

Conference Call:

 

U.S. (888) 886-7786

 

 

International +1 (416) 764-8658

 

 

Conference ID is 36818707

   

Webcast:

 

Live and replay webcast of the call with slides will be available here.

About OmniAb®

OmniAb, Inc.’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities in emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others. The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

For more information, please visit www.omniab.com.


Contacts

OmniAb, Inc.
Neha Singh
investors@OmniAb.com
Twitter @OmniAbTech
(510) 768-7760

LHA Investor Relations
Yvonne Briggs
ybriggs@lhai.com
(310) 691-7100

Editor Details

  • Company:
    • Businesswire
Last Updated: 01-May-2023